Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03993106 · ClinicalTrials.gov registry record · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
A Phase 2 study of Kaposi Sarcoma, sponsored by Vasgene Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
- 3
- Study locations
NCT03993106: Recruiting Phase 2 study of Kaposi Sarcoma, sponsored by Vasgene Therapeutics.
NCT03993106 is a Phase 2 study of Kaposi Sarcoma that is actively recruiting participants, run by Vasgene Therapeutics. The registered enrollment target is 65 participants, below the 97-participant average among 13 other Kaposi Sarcoma trials with a reported enrollment target (33% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03993106, a Phase 2 study of Kaposi Sarcoma, is actively recruiting participants, sponsored by Vasgene Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
- 3
- Study locations
Study Summary
sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor. The purpose of this study is to learn if sEphB4-HSA will decrease the number or size of Kaposi sarcoma lesions in people.
Conditions Studied
Interventions
- DRUG sEphB4-HSA
Study Locations (3)
California
- AIDS Healthcare Foundation - Beverly Hills
Florida
- CAN (Community AIDS Network) Community Health - Sarasota
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2020-09-17 |
| Est. Completion | 2025-06 |
| Phase | Phase 2 |
What NCT03993106 shows while recruiting
NCT03993106 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 97-participant average among 13 other Kaposi Sarcoma trials with a reported enrollment target (33% lower).
The record links to 1 condition, with Kaposi Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which sEphB4-HSA is the first listed.
NCT03993106 reports a single indexed study location in California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT03993106 about?
NCT03993106 is a clinical study titled "A Study of sEphB4-HSA in Kaposi Sarcoma". sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor. The purpose of this study is to learn if sEphB4-HSA will decrease the number or size of Kaposi sarcoma lesions in people.
What is the current status of trial NCT03993106?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2020-09-17. Estimated completion is 2025-06.
What conditions does trial NCT03993106 study?
This clinical trial studies the following conditions: Kaposi Sarcoma.
What interventions are being tested in trial NCT03993106?
The interventions under investigation include: sEphB4-HSA (DRUG).
Who is sponsoring clinical trial NCT03993106?
This trial is sponsored by Vasgene Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03993106 being conducted?
This trial has 3 study locations across California, Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kaposi Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03993106's enrollment target sits among peer trials
65 6th of 13 higher than 8 of 13 other Kaposi Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kaposi Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Ixazomib for Kaposi Sarcoma
RECRUITING · Phase 2
-
Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)
RECRUITING · Phase 2
-
Propranolol for the Treatment of Kaposi Sarcoma in Adults
RECRUITING · Phase 2
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV
RECRUITING · Phase 1
-
PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT04028063 · 65 participants · Phase 2
Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI